Ortenau Klinikum
- Address
- lock Available on a paid plan
Hemic and Lymphatic Diseases Research
The department of Medizinische Klinik II, Hämatologie, Onkologie at Ortenau Klinikum concentrates on blood‑related cancers, including Acute Myeloid Leukemia, Acute lymphoblastic leukemia, Myelodysplastic syndrome, and various lymphomas. Current studies aim to test innovative targeted agents, improve event‑free survival, and reduce treatment‑related toxicity for patients with high‑risk hematologic malignancies.
- Targeted BCL‑2 inhibition combined with standard induction in newly diagnosed AML
- IDH‑mutant specific therapy (ivosidenib/enasidenib) alongside chemotherapy for AML/MDS
- FLT3 inhibition (gilteritinib vs. midostaurin) in frontline AML treatment
- Sequential TKI, chemotherapy, and blinatumomab for Ph+ ALL
- Bispecific antibody (glofitamab) plus polatuzumab vedotin and rituximab for aggressive B‑cell lymphoma
Across the 13 active trials, investigators are evaluating whether these novel approaches can prolong overall survival and achieve deeper molecular remissions, positioning the site as a hub for cutting‑edge hematologic oncology research.
Solid Tumor Oncology Research
In addition to hematologic work, the clinic conducts extensive studies on solid tumors such as triple‑negative breast cancer, ER+/HER2‑ breast cancer, and advanced high‑grade ovarian, peritoneal, and fallopian tube cancers. The trials focus on integrating immunotherapy, endocrine strategies, and PARP inhibition to improve progression‑free survival and reduce disease recurrence.
- Atezolizumab added to neoadjuvant paclitaxel/carboplatin in triple‑negative breast cancer
- Elacestrant versus standard endocrine therapy in ctDNA‑positive early breast cancer
- Niraparib alone or combined with bevacizumab after chemotherapy for advanced ovarian cancer
- Pembrolizumab followed by consolidation radiotherapy in early‑stage favorable Hodgkin lymphoma
- Dual antibody‑drug conjugate (loncastuximab tesirine) and bispecific antibody (epcoritamab) for relapsed diffuse large B‑cell lymphoma
These investigations aim to establish more effective, less toxic treatment regimens and to expand personalized therapy options for patients across Europe, reinforcing the site’s role in innovative solid‑tumor clinical research.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 therapeutic areas and 15 of 60 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 60 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 7 by active trials.
- 1Universitaet Muenster2active
lock +6 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1University Of Cologne3trials
lock +4 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Ortenau Klinikum
lock Showing 1 of 18 trials — the rest is available on a paid plan.
IMP list
lock Showing 1 of 60 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Paclitaxel | 3 | Unknown | 2016-11-07 | 2022-08-31 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.